Alkermes plc Stock
Price
Target price
?
?
-1.590%
-0.4
-1.590%
€38.70
07:31 / Stuttgart Stock Exchange
WKN: A1JKVH / Symbol: ALKS / Name: Alkermes / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Alkermes plc Stock
We can see a decrease in the price for Alkermes plc. Compared to yesterday it has lost -€0.400 (-1.590%).
With 17 Buy predictions and not the single Sell prediction the community is currently very high on Alkermes plc.
With a target price of 38 € there is a hugely positive potential of 53.23% for Alkermes plc compared to the current price of 24.8 €.
Pros and Cons of Alkermes plc in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Alkermes plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Alkermes plc | -1.590% | 1.613% | -8.029% | -13.699% | -10.000% | 5.860% | 64.706% |
| Ironwood Pharmaceuticals | 0.000% | -3.311% | 63.128% | -7.006% | -30.476% | -74.007% | -69.741% |
| Novocure Ltd | 1.730% | 2.979% | 9.759% | -60.824% | -64.389% | -86.086% | -92.032% |
| Iovance Biotherapeutics Inc. | 0.370% | 3.339% | -0.202% | -76.819% | -71.321% | -70.822% | -94.899% |
Comments
Alkermes (NASDAQ:ALKS) had its price target raised by analysts at Truist Financial Corporation from $50.00 to $55.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ALKS provided by MarketBeat
Alkermes (NASDAQ:ALKS) had its price target lowered by analysts at Wells Fargo & Company from $42.00 to $37.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for ALKS provided by MarketBeat
Alkermes (NASDAQ:ALKS) had its price target lowered by analysts at Deutsche Bank Aktiengesellschaft from $55.00 to $45.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ALKS provided by MarketBeat
News
Alkermes Q2 Sales Up 14 Percent
Alkermes Plc (NASDAQ:ALKS), a neuroscience-focused biopharmaceutical company, released its second quarter 2025 results on July 29, 2025. The standout news was a significant outperformance versus
